No Picture
News

Helsinn and MEI Pharma Announce Updated Clinical Data from the Phase 2 Study Evaluating Pracinostat in Combination with Azacitidine in Patients with High/Very-high Risk Myelodysplastic Syndromes

– Data to be Featured in the American Society of Clinical Oncology Annual 2020 Virtual Scientific Program on May 29, 2020 at 8:00 a.m. EDT –

LUGANO, Switzerland and SAN DIEGO, May 13, 2020 /PRNewswire/ — Helsinn Group, a Swiss pharmaceutical group f… […]

No Picture
News

DTx Pharma Receives Prestigious Funding Award to Support Research in Neurodegenerative Diseases of the CNS

-DTx was one of 8 grantees selected out of more than 100 academic and company applicants worldwide-

SAN DIEGO, May 13, 2020 /PRNewswire/ — DTx Pharma, Inc. (DTx), a privately-held biotechnology company creating novel RNA-based therapeutics to treat … […]

No Picture
News

Cardiff Oncology Enters Agreement with PoC Capital to Fund Phase 2 Clinical Trial of Onvansertib in KRAS-Mutated Metastatic Colorectal Cancer (mCRC)

– Funding will also enable the addition of new trial sites to accelerate completion of the Phase 2 clinical trial- Data continues to demonstrate the safety and efficacy of onvansertib as a promising new treatment for patients with KRAS-mutated mCRC

S… […]

No Picture
News

DelMar Pharmaceuticals Announces Fiscal Third Quarter 2020 Financial Results and Recent Corporate Updates

SAN DIEGO, May 13, 2020 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announced its financial results for the thre… […]

No Picture
News

Viking Therapeutics Announces 2020 Annual Meeting of Stockholders to be Held as Virtual Meeting

SAN DIEGO, May 12, 2020 /PRNewswire/ — Viking Therapeutics, Inc. (Viking) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced a change to it… […]

No Picture
News

Trovagene Announces Changing of Company Name to Cardiff Oncology and Appointment of Mark Erlander, PhD, as Chief Executive Officer

– New corporate name, Cardiff Oncology, reflects the Company’s mission and commitment to turning the tide on cancer by developing new treatment options for cancer patients- Effective May 8th, Dr. Thomas Adams will transition his role from Chairman and … […]

No Picture
News

Neurocrine Biosciences to Present at Bank of America Merrill Lynch Health Care Conference 2020

Live Audio Webcast will be on May 12, 2020

SAN DIEGO, May 5, 2020 /PRNewswire/ –?Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Bank of America Merrill Lynch Health Care Conference 2020 at 2:20 p.m. ET on Tuesday, May 12, 2020. Kevi… […]